Skip to search formSkip to main contentSkip to account menu

BMS 354825

Known as: 354825, BMS, BMS-354825, BMS354825 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dasatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
2011
2011
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Ras/MEK/ERK pathway activation represents an important compensatory response of human multiple myeloma (MM) cells to checkpoint… 
2009
2009
The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.
2006
2006
Protein Tyrosine Kinases. From Inhibitors to Useful Drugs
Protein tyrosine kinases (PTK) play a fundamental role in signal transduction pathways. Deregulated tyrosine kinase activity has… 
2006
2006
Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003).
3046 Background: Dasatinib - an inhibitor of several oncologenic kinases including BCR-ABL and SRC - has demonstrated efficacy in… 
2006
2006
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.
Imatinib (Glivec; Novartis, Basel, Switzerland), specifically inhibiting ABL kinase, has evidenced an important role in chronic… 
2005
2005
Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).
Resistance to imatinib is a growing concern in CML, particularly in advanced disease. The most common cause of resistance is… 
2005
2005
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.
The genetic heterogeneity of multiple myeloma (MM) and the evolution of the disease as it progresses result in a multiplicity of… 
2004
2004
BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.
Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated tyrosine kinase, the BCR-ABL… 
2004
2004
BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant.
The vast majority of systemic mastocytosis cases are associated with a somatic KIT oncoprotein point mutation which substitutes a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)